Applied DNA and Spindle Biotech execute LOI

By The Science Advisory Board staff writers

March 15, 2022 -- Applied DNA Sciences and Spindle Biotech have executed a nonbinding letter of intent (LOI) that outlines the terms of a collaborative research agreement to bring together Applied DNA's LinearDNA platform and Spindle Biotech's proprietary, high yield RNA manufacturing system, the companies said in a press release.

Under the terms of the agreement, the companies will investigate the feasibility of using the LinearDNA platform to produce chemically modified DNA templates for use in Spindle Biotech's system. The companies hope for a simplified, high yield, and 100% cell-free workflow.

The use of LinearDNA as an IVT template removes several complex manufacturing steps necessitated by plasmid DNA, the companies said. Following initial validation work, the companies said they will explore the commercialization of an mRNA production system.

No financial details were disclosed.

Applied DNA and EvviVax publish data for potential cancer immunotherapy
Applied DNA Sciences and EvviVax have published a manuscript detailing a preclinical study showing that LinearDNA vaccines used for cancer immunotherapy...

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter